Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TK216 in Relapsed/Refractory Acute Myeloid Leukemia
NCT03752138Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of TK216 in acute myeloid leukemia (AML) (5 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of adverse events up to 30 days and Maximum Tolerated Dose. Planned start Mar 2019; status: withdrawn.
02
Drugs
TK216
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03752138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03752138.